No Data
No Data
Yiqiao Shenzhou (301047.SZ): Has repurchased 1.80% of the shares.
On July 2, Gelonhui reported that Yiqiao Shenzhou (301047.SZ) announced that as of June 30, 2024, the company used its own funds to implement repurchases through the stock repurchase special securities account in a centralized bidding trading manner. The accumulated repurchased shares amounted to 2,323,409 shares, accounting for 1.80% of the company's current total share capital. The highest fill price was RMB 74.67/share, the lowest fill price was RMB 58.50/share, and the total amount traded was RMB 156,834,500 (excluding transaction costs).
Yiqiao Shenzhou (301047.SZ): 2023 equity distribution of 10 distributions of 20 yuan Equity Registration Day May 22
Gelonghui, May 16 | Yiqiao Shenzhou (301047.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 20.0000 (tax included) to all shareholders for every 10 shares based on the company's current total share capital excluding 127,760,391 shares after 1,439,609 shares already repurchased. The share registration date for this equity distribution is May 22, 2024, and the ex-dividend date is May 23, 2024.
Yiqiao Shenzhou (301047.SZ): Currently, pharmaceutical companies account for a relatively large share of direct sales revenue
Gelonghui May 10 丨 Yiqiao Shenzhou (301047.SZ) held a performance briefing on May 9, 2024 to discuss “What is the company's business share in scientific research institutions and pharmaceutical companies?” The company replied that the company's product line covers a wide range of products and can be used to support basic life science research by scientific research institutions and innovative research and development by pharmaceutical companies, and that there are different domestic and international competition situations in different fields of reagents and services. Currently, pharmaceutical companies account for a relatively large share of direct sales revenue.
Pharmaceutical stocks rose and spread in the afternoon. Various branches such as synthetic biology, peptide drugs, and CRO resonated. Joint Pharmaceutical and Xiangxue Pharmaceutical rose and stopped 20CM, Shutai Shenzhou rose more than 10%, and Tuoxin Ph
Pharmaceutical stocks rose and spread in the afternoon. Various branches such as synthetic biology, peptide drugs, and CRO resonated. Joint Pharmaceutical and Xiangxue Pharmaceutical rose and stopped 20CM, Shutai Shenzhou rose more than 10%, and Tuoxin Pharmaceutical, Yiqiao Shenzhou, and Heyuan Biotech rose more than 10%.
The synthetic biology concept bottomed out and Ruifeng Hi-Tech rose by more than 15%. Previously, Blue Biotech went out of the 6-game market, with Yiqiao Shenzhou, Offshore Protein, Xinghu Technology, and Lukang Pharmaceutical leading the way in gains.
The synthetic biology concept bottomed out and Ruifeng Hi-Tech rose by more than 15%. Previously, Blue Biotech went out of the 6-game market, with Yiqiao Shenzhou, Offshore Protein, Xinghu Technology, and Lukang Pharmaceutical leading the way in gains.
Express News | Yiqiao Shenzhou: Net profit of 43.7615 million yuan in the first quarter decreased by 47.71% year-on-year
No Data